Erythrocyte sedimentation rate (ESR) can be defined as the rate at which red blood cells or erythrocytes sediment in a period of one hour. ESR is usually measured in millimeter per hour (mm/hr) and a value above 100 mm/hr indicates a disease condition, such as a disease that causes inflammation, active infection, cancer, heart disease, kidney disease, blood disease, diabetes, and collagen vascular disease. However, ESR is a non-specific test for inflammation and is used in conjunction with other tests such as C-reactive protein. Normal ESR result does not rule out the possibility of inflammation. Similarly, an elevated ESR without any symptoms of the disease does not aid in making any medical decision. ESR analyzers are devices employed to measure the sedimentation rate of erythrocytes for an accurate reading. Automated ESR analyzers need to comply with the 2011-published Clinical and Laboratory Standards Institute (CLSI) guidelines for measuring ESR. The analyzer works on the basic principle of Westergren’s method followed to determine ESR.
The ESR analyzers market can be segmented based on modality, end-user, and region. In terms of modality, the market can be segmented into automatic analyzers, semi-automatic analyzers, and manual analyzers. Based on end-user, the ESR analyzers market can be segmented into hospitals, diagnostic laboratories, and academic institutions. In terms of region, the ESR analyzers market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa.
ESR is one of the basic hematology tests performed to identify various disease conditions, which would contribute to the growth of the ESR analyzers market. Technological upgrades leading to the development of automated ESR analyzers from manual ESR analyzers would also contribute to the growth of the market. In addition, the increasing number of infections leading to various health hazards would contribute to the rising number of ESR tests, which in turn would drive the ESR analyzers market in the near future. However, the non-specificity of the tests and the necessity for other tests to be performed to confirm the diseased condition could have a negative impact on the ESR analyzers market, as demand for specific tests increases. Furthermore, false negative results of ESR due to the effect of drugs such as oral contraceptives, dextran, methyldopa, penicillamine procainamide, theophylline, vitamin A, aspirin, cortisone, and quinine also make ESR less desirable, thereby impacting the growth of the ESR analyzers market.
Automatic analyzers are expected to dominate the ESR analyzers market during the forecast period, owing to their abilities to enhance the workflow and turnaround time. Diagnostic laboratories and hospitals are expected to be the leading segments of the ESR analyzers market. Geographically, North America is expected to be the major market for ESR analyzers. Growth of the market in the region can be attributed to the well-developed health care infrastructure in the region. Asia Pacific is expected to witness the highest growth rate during the forecast period, owing to increasing infections, evolution of new diseases, and poor sanitation conditions which lead to increased infections among the population. In addition, government focus on enhancing the health care infrastructure and providing better health care facilities to the population contribute to the growth of the ESR analyzers market in Asia Pacific.
Leading players in the ESR analyzers market include Sysmex, R&R Mechatronics International B.V., TRANSASIA Bio Medicals Ltd., Diesse Diagnostica Senese Spa, Vital Diagnostics, Caretium Medical Instruments Co, Limited, Grifols, S.A., Beckman Coulter, Inc., ALCOR Scientific, Inc., Thermo Fisher Scientific, Perlong Medical, BPC Biosed Srl, and SFRI.